Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia
Vincent A. Jourdain, Katharina A. Schindlbeck, Chris C. Tang, Martin Niethammer, Yoon Young Choi, Daniel Markowitz, Amir Nazem, Dominic Nardi, Nicholas Carras, Andrew Feigin, Yilong Ma, Shichun Peng, Vijay Dhawan, David Eidelberg
Vincent A. Jourdain, Katharina A. Schindlbeck, Chris C. Tang, Martin Niethammer, Yoon Young Choi, Daniel Markowitz, Amir Nazem, Dominic Nardi, Nicholas Carras, Andrew Feigin, Yilong Ma, Shichun Peng, Vijay Dhawan, David Eidelberg
View: Text | PDF
Research Article Neuroscience

Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia

  • Text
  • PDF
Abstract

In a rodent model of Parkinson’s disease (PD), levodopa-induced involuntary movements have been linked to striatal angiogenesis — a process that is difficult to document in living human subjects. Angiogenesis can be accompanied by localized increases in cerebral blood flow (CBF) responses to hypercapnia. We therefore explored the possibility that, in the absence of levodopa, local hypercapnic CBF responses are abnormally increased in PD patients with levodopa-induced dyskinesias (LID) but not in their nondyskinetic (NLID) counterparts. We used H215O PET to scan 24 unmedicated PD subjects (12 LID and 12 NLID) and 12 matched healthy subjects in the rest state under normocapnic and hypercapnic conditions. Hypercapnic CBF responses were compared to corresponding levodopa responses from the same subjects. Group differences in hypercapnic vasoreactivity were significant only in the posterior putamen, with greater CBF responses in LID subjects compared with the other subjects. Hypercapnic and levodopa-mediated CBF responses measured in this region exhibited distinct associations with disease severity: the former correlated with off-state motor disability ratings but not symptom duration, whereas the latter correlated with symptom duration but not motor disability. These are the first in vivo human findings linking LID to microvascular changes in the basal ganglia.

Authors

Vincent A. Jourdain, Katharina A. Schindlbeck, Chris C. Tang, Martin Niethammer, Yoon Young Choi, Daniel Markowitz, Amir Nazem, Dominic Nardi, Nicholas Carras, Andrew Feigin, Yilong Ma, Shichun Peng, Vijay Dhawan, David Eidelberg

×

Figure 1

Hypercapnic cerebral blood flow responses in the putamen levodopa dissociation region.

Options: View larger image (or click on image) Download as PowerPoint
Hypercapnic cerebral blood flow responses in the putamen levodopa dissoc...
Globally normalized cerebral blood flow (CBF) values were measured in the unmedicated state under normocapnic (NC) and hypercapnic (HC) conditions in the area of dissociated vasomotor and metabolic levodopa responses previously described in the posterior putamen (see Results). (A) Significant CBF changes were seen in this region with consistent hypercapnic increases in the levodopa-induced dyskinesia (LID; n = 12), non-LID (NLID; n = 12), and normal control (NL; n = 12) groups. (CBF values measured in the NC and HC conditions are displayed for the subjects in each group using box-and-whisker plots. Horizontal arrows denote significance levels [P values] for each group according to the paired Student’s t test. The number of violations [subjects in whom HC was either equal to or lower than the corresponding NC value] are given in parentheses as the fraction of the total number of subjects in each group [see Results].) (B) Display of the hypercapnic CBF responses (ΔHC = CBFHC – CBFNC) for each group measured in the putamen levodopa dissociation region (see Results). Responses in this region were greater in LID subjects compared with NLID and NL subjects. (Horizontal arrows denote significance levels [P values] for group comparisons according to the post-hoc Bonferroni test of 1-way ANOVA [see Methods].)

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts